About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Not Yet RecruitingNA

BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

A Single-arm Multi-center Trial of BCMA/CD3 Bispecific Antibody for Relapsed/Refractory AL Amyloidosis or Newly Diagnosed AL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy

NCT06769555•Institute of Hematology & Blood Diseases Hospital, China

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

AL Amyloidosis

Interventions

CM-336 BCMA/CD3 bispecific antibody

Key Dates

Start Date

January 1, 2025

Primary Completion Date

August 1, 2026

Completion Date

August 1, 2028

Last Updated

January 10, 2025

Related Studies

Promoting Diagnosis and Management of AL in Italy (ProDigALIty)

NCT06383143

AL AmyloidosisSmoldering Multiple Myeloma+1 more

Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

NCT06192979

Amyloidosis; SystemicAL Amyloidosis

RECRUITINGPhase 1

Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis

NCT07250269

Relapsed/Refractory AL Amyloidosis

RECRUITINGPhase 3

Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

NCT06022939

A Registry of AL Amyloidosis (ReAL)

NCT04839003

RECRUITINGPhase 2

Isatuximab Plus Pomalidomide and Dexamethasone Association for Patients With AL Amyloidosis Not in VGPR or Better After Any Previous Therapy

NCT05066607

View all related studies

Contacts

Gang An, PhD, MD

CONTACT

00861350218110 angang@ihcams.ac.cn

Jian Cui, MBBS

CONTACT

008617711354648 cuijian@ihcams.ac.cn

Sponsors

Lead Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Collaborators

Keymed Biosciences Co.Ltd

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 10, 2025Data synced to Clareo: April 27, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions